logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
E

Eva Domingo-Doménech

Institut Català d'Oncologia
H指数:34
被引数:4,823

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-Bulky Hodgkin Lymphoma, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles: The RAFTING Trial Protocol

无放射治疗对低代谢肿瘤体积和2个化疗周期后中期PET阴性定义的良好预后早期非巨大肿块霍奇金淋巴瘤初始治疗的RAFTING试验方案

Biomedicines
IF3.9
2026-08-290
OA
Kateryna Filonenko; Marco Picardi; Stephane Chauvie; Andrea Riccardo Filippi; Maria Cristina Pirosa; Luca Guerra; Federico Fallanca; Marta Bednarek; Michał Kurlapski; Eva Domingo-Domenech; Andrea Visentin; Caterina Patti; Ramón García-Sanz; Javier Nunez; Javier Lopez-Jiménez; Agnieszka Giza; Adam Wyszomirski; Alessandro Rambaldi; Davide Rossi; Anna Sureda; Andrea Gallamini; Jan Maciej Zaucha
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

更正: Brentuximab vedotin联合化疗治疗一线系统性间变性大细胞淋巴瘤: 5年随访时ECHELON-2研究的亚组分析

Blood Cancer Journal
IF11.6
2026-01-280
OAAI
Eva Domingo-Domènech; Barbara Pro; Tim Illidge; Steven Horwitz; Lorenz Trumper; Swami Iyer; Ranjana Advani; Nancy L. Bartlett; Jacob Haaber Christensen; Won-Seog Kim; Tatyana Feldman; Ilseung Choi; Giuseppe Gritti; David Belada; Andrei Shustov; Arpad Illes; Pier Luigi Zinzani; Andreas Hüttmann; Marek Trneny; Steven Le Gouill; Deepa Jagadeesh; Jonathan W. Friedberg; Meredith Little; Cassie Dong; Michelle Fanale; Keenan Fenton; Kerry J. Savage
Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma

zanubrutinib在西班牙复发性/难治性边缘区淋巴瘤患者中的真实世界有效性与安全性

Blood Advances
IF7.1
2026-01-010
OA
Fernando Martín‐Moro; Ana Muntañola; Xabier Gutiérrez López de Ocáriz; Maria Sofia Vazquez Diaz; LUCIA MORAIS; Itxaso Amarika; Ramón Díez-Feijoo; Mariana Bastos‐Oreiro; B. de la Cruz Benito; Javier Marco; Sergio Ramos-Cillán; Ana Jiménez-Ubieto; Pablo Galindo-Navarro; Juan Gonzalo Correa; Esperanza Lavilla; Cristina García-Herce; Miriam Moreno; Eva Domingo‐Doménech; Nazaret Domínguez; Aranzazu Alonso; María José Otero; Alessandra Comai; María L. Bengochea-Casado; Carolina Villegas; Norma Carmen Gutierrez; Rafael Lluch; Sara Fernández‐Luis; Alfons Soler; Jimena Cannata‐Ortiz; Ángeles Medina; Sofia Martin-Consuegra; Marta Aceituno; Paola Villafuerte‐Gutierrez; D. de Miguel Llorente; José-María Arguiñano; Javier López-Marín; Lucía Villalón; Horacio Martín Gulino; Armando López‐Guillermo; Antonio Salar
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

纳武利尤单抗联合 Brentuximab Vedotin 治疗复发/难治性弥漫性大B细胞淋巴瘤

Future Oncology
IF2.6
2025-12-100
OAAI
Nathalie A. Johnson; Pier Luigi Zinzani; Eva Domingo-Domenech; Joshua Brody; Justin Kline; Bijal Dinesh Shah; Amitkumar Nitinkumar Mehta; Herve Ghesquieres; Kerry J. Savage; Paul M. Barr; Armando Santoro; Silvia Ferrari; David Cunningham; Graham P. Collins; Michelle Fanale; Jennifer Krajewski; Alev Akyol; Russell Crowe; Rachael Wen; John Kuruvilla
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

塔fasitamab、lenalidomide和阿利霉素在复发或难治性滤泡性淋巴瘤（inMIND）中的研究：一项全球性、III期、随机对照试验

The Lancet
IF97.3
2025-12-050
PRE
Laurie H Sehn; Kai Hübel; Stefano Luminari; Christian W Scholz; Antonio Salar; Shankara Paneesha; Björn Engelbrekt Wahlin; Panayiotis Panayiotidis; Hui-Peng Lee; Ana Jiménez-Ubieto; Juan-Manuel Sancho; Tae Min Kim; Eva Domingo Domenech; Takahiro Kumode; Christina Poh; Catherine Thieblemont; Dries Deeren; Edwin de Wit; Michael Arbushites; Irene Vassallo
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma

PET4反应与ECHELON-2试验中CD30+外周T细胞淋巴瘤患者接受BV-CHP vs CHOP治疗的结局相关性研究

Blood Advances
IF7.1
2025-08-210
OAAI
Swaminathan Iyer; Neha Mehta-Shah; Ranjana Advani; Nancy L. Bartlett; Jacob H. Christensen; Franck Morschhauser; Eva Domingo-Domenech; Giuseppe Rossi; Won Seog Kim; Onder Alpdogan; Tatyana A. Feldman; Vincent Camus; Giuseppe Gritti; Pier Luigi Zinzani; David Belada; Jiri Mayer; Ilseung Choi; June-Won Cheong; Evelyn Rustia; Keenan Fenton
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

brentuximab vedotin联合化疗用于一线系统性间变性大细胞淋巴瘤的治疗：ECHELON-2研究5年随访的亚组分析

Blood Cancer Journal
IF11.6
2025-08-010
OAAI
Eva Domingo-Domènech; Barbara Pro; Tim Illidge; Steven Horwitz; Lorenz Trumper; Swami Iyer; Ranjana Advani; Nancy L. Bartlett; Jacob Haaber Christensen; Won-Seog Kim; Tatyana Feldman; Ilseung Choi; Giuseppe Gritti; David Belada; Andrei Shustov; Arpad Illes; Pier Luigi Zinzani; Andreas Hüttmann; Marek Trneny; Steven Le Gouill; Deepa Jagadeesh; Jonathan W. Friedberg; Meredith Little; Cassie Dong; Michelle Fanale; Keenan Fenton; Kerry J. Savage
A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial

一项Ib/II期临床试验，将brentuximab vedotin与环磷酰胺、丙卡巴肼、泼尼松、依托泊苷和米托蒽醌（BrEPEM）联合用于未经治疗的老年经典型霍奇金淋巴瘤患者：一项多中心GELTAMO试验

British Journal of Haematology
IF3.8
2025-07-250
PRE
Cecilia Carpio; Fátima de la Cruz-Vicente; Ramon García-Sanz; Izaskun Zeberio; Cristina Barrenetxea; Eva Domingo-Domenech; Mariana Bastos; Araceli Rubio Martinez; Pilar Gómez-Prieto; Antonia Rodriguez; Maria Casanova; Antonia Cladera-Serra; Javier Nuñez Cespedes; Carmen Martínez; Miriam Moreno-Velázquez; Eduardo Garcia-Galea; Pau Abrisqueta; Francesc Bosch
Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Tafasitamab 联合 Lenalidomide 和 Rituximab 治疗复发或难治性滤泡性淋巴瘤：来自一项 3 期研究（inMIND）的结果

BLOOD
IF23.1
2024-11-253
PRE
Sehn, Laurie H.; Luminari, Stefano; Scholz, Christian W.; Huebel, Kai; Salar, Antonio; Paneesha, Shankara; Wahlin, Bjorn E.; Panayiotidis, Panayiotis; Lee, Hui-Peng; Ubieto, Ana Jimenez; Sancho, Juan-Manuel; Kim, Tae Min; Domenech, Eva Domingo; Kumode, Takahiro; Poh, Christina; Thieblemont, Catherine; Deeren, Dries; de Wit, Edwin; Arbushites, Michael; Casadebaig, Marie-Laure; Trneny, Marek
Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

同种异基因造血细胞移植巩固治疗与无巩固治疗对接受双特异性抗体治疗的非霍奇金淋巴瘤患者的影响

BLOOD
IF23.1
2024-11-050
PRE
Losi, Giulia; Pena, Marta; Qualls, David A.; Crombie, Jennifer L.; Mariotti, Jacopo; Bramanti, Stefania; Fabbri, Nicole; Serna, Angel; Serroukh, Yasmina I. M.; Balaguer Rosello, Aitana; van der Poel, Marjolein W. M.; Hsu, Ya-Ting; Jimenez Ubieto, Ana; McKinnely, Christopher; Armand, Philippe; Pena, Felipe; Carro, Itziar; Martinez, Carolina; Domingo Domenech, Eva; Lopez Pereira, Patricia; Arevalo Leon, Carolina Esther; Gonzalez Barca, Eva; Sureda Balari, Anna; Mussetti, Alberto
Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Brentuximab-Vedotin在复发性/难治性(R/R)CD30+恶性肿瘤患者中再次治疗的有效性与安全性：一项在西班牙进行的回顾性病历审查研究。Believe研究。NCT:04998331

BLOOD
IF23.1
2024-11-050
PRE
Garcia-Sanz, Ramon; Balari, Anna Sureda; Domenech, Eva Domingo; Huelva, Francisco Javier Capote; Gutierrez, Antonio; Izquierdo, Antonia Rodriguez; De Domingo, Marta Grande; Baeza, Lourdes
A Multicenter, Open-Label, Phase 3, Randomized Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients with Relapsed/Refractory Nodal T Cell Lymphoma with T Follicular Helper Phenotype

一项多中心、开放标签、III期、随机对照试验，比较度维利司与研究者选择的吉西他滨或博纳吐胺在复发/难治性结外T细胞淋巴瘤（伴T滤泡辅助细胞表型）患者中的疗效。

BLOOD
IF23.1
2024-11-050
PRE
Cwynarski, Kate; Domenech, Eva Domingo; Sidransky, David; Bentur, Ohad S.; Zinzani, Pier Luigi
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
BLOOD ADVANCES
IF7.1
2024-08-302
OAAI
Witzig, Thomas; Sokol, Lubomir; Kim, Won Seog; Vicente, Fatima de la Cruz; Garcia-Sancho, Alejandro Martin; Advani, Ranjana; Vidal, Jose Maria Roncero; Navarrete, Raquel de Ona; Marin-Niebla, Ana; Izquierdo, Antonia Rodriguez; Terol, Maria Jose; Domingo-Domenech, Eva; Saunders, Andrew; Bendris, Nawal; Mackey, Julie; Leoni, Mollie; Foss, Francine
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Nivolumab联合brentuximab vedotin治疗复发/难治性外周T细胞淋巴瘤和皮肤T细胞淋巴瘤

BLOOD ADVANCES
IF7.1
2024-05-201
OAAI
Zinzani, Pier Luigi; Salles, Gilles; Moskowitz, Alison J.; Santoro, Armando; Mehta, Amitkumar; Barr, Paul M.; Mehta-Shah, Neha; Collins, Graham P.; Ansell, Stephen M.; Brody, Joshua D.; Domingo-Domenech, Eva; Johnson, Nathalie A.; Cunningham, David; Ferrari, Silvia; Lisano, Julie; Krajewski, Jennifer; Wen, Rachael; Akyol, Alev; Crowe, Russell; Savage, Kerry J.
The Etiology, Antibiotic Therapy and Outcomes of Bacteremic Skin and Soft-Tissue Infections in Onco-Hematological Patients

肿瘤性血液病患者细菌性皮肤和软组织感染的病因，抗生素治疗和结局

ANTIBIOTICS-BASEL
IF4.6
2023-12-131
OA
Castelli, Valeria; Sastre-Escola, Enric; Puerta-Alcalde, Pedro; Huete-Alava, Leyre; Laporte-Amargos, Julia; Bergas, Alba; Chumbita, Mariana; Marin, Mar; Domingo-Domenech, Eva; Badia-Tejero, Ana Maria; Pons-Oltra, Paula; Garcia-Vidal, Carolina; Carratala, Jordi; Gudiol, Carlota

研究方向

暂未获取到该数据
A
Anna Sureda
H 指数:93论文数:1,124被引数:3.4万
E
Eva González‐Barca
H 指数:44论文数:373被引数:7,159
P
Pier Luigi Zinzani
H 指数:117论文数:1,841被引数:6.1万
A
Antonio Salar
H 指数:43论文数:362被引数:6,672
R
Ranjana H. Advani
H 指数:100论文数:840被引数:4.7万
K
Kerry J. Savage
H 指数:84论文数:639被引数:3.7万
S
Steven M. Horwitz
H 指数:69论文数:550被引数:1.9万
R
Ramón García‐Sánz
H 指数:80论文数:727被引数:2.7万
M
Michelle A. Fanale
H 指数:54论文数:473被引数:1.6万
J
Jacob Haaber Christensen
H 指数:20论文数:161被引数:2,962